

Dissertation Title

This manuscript ([permalink](#)) was automatically generated from [greenelab/ben_heil_dissertation@f08350c](#) on November 9, 2022.

Authors

- **Benjamin J. Heil**

 [0000-0002-2811-1031](#) ·  [benheil](#) ·  [autobencoder](#)

Genomics and Computational Biology Graduate Group, University of Pennsylvania

✉ — Correspondence possible via [GitHub Issues](#)

Abstract

Introduction

Overall Intro

Linear models background

Disease prediction review

The human transcriptome provides a rich source of information about both healthy and disease states. Not only is gene expression information useful for learning novel biological phenomena, it can also be used to diagnose and predict diseases. These predictions have become more powerful in recent years as the field of machine learning has developed more methods. In this paper we review supervised machine learning methods applied to predict various phenotypes from gene expression, with a focus on the challenges in the field and what is being done to overcome them. We close the review with potential areas for future research, as well as our perspectives on the strengths and weaknesses of supervised learning for phenotype prediction.

Introduction

Over the past few decades a number of tools for measuring gene expression have been developed. As proteomics is currently difficult to do at a large scale, gene expression quantification methods are our best way to measure cells' internal states. While this wealth of information is promising, gene expression data is more difficult to work with than one might think. The high dimensionality and instrument-driven variation require sophisticated techniques to separate the signal from the noise.

One such class of techniques is the set of methods from machine learning. Machine learning methods depend on the assumption that there are patterns in data that can be learned to make predictions about future data. Luckily, different people respond to the same disease in similar ways (for some diseases). Learning genes that indicate an inflammatory response, for example, can help a machine learning model learn the difference between healthy and diseased expression samples.

There are many varieties of machine learning algorithms, so the scope of this paper is limited to analysis of supervised machine learning methods for phenotype prediction. Supervised machine learning is a paradigm where the model attempts to predict labels. For example, a model that predicts whether someone has lupus based on their gene expression data [\[1\]](#) is a supervised learning model. In contrast, techniques for grouping data together without having phenotype labels are called unsupervised methods. While these methods are also commonly used in computational biology [\[2,3,4\]](#), we will not be discussing them here.

The purpose of this review is to explain and analyze the various approaches that are used to predict phenotypes. Each section of the review is centered around one of the challenges ubiquitous in using supervised machine learning techniques on gene expression data. We hope to explain what has been tried and what the consensus for handling the challenge, if one exists. The review will conclude with a section outlining promising new methods and areas where further study is needed.

If the field succeeds in addressing all the challenges, the payoffs will be substantial. Being able to predict and diagnose diseases from whole blood gene expression is particularly interesting. With sufficiently advanced analysis, invasive cancer biopsies might be able to be replaced with simple blood draws [\[4\]](#). If not, there are already diagnostics that predict various cancer aspects from biopsy gene

expression [5]. It may also be possible to diagnose common diseases based on blood gene expression [6,7,8,9], or even rare ones [10].

Background

The techniques for measuring gene expression and for analyzing it have changed dramatically over the past few decades. This section aims to explain what some of those changes are and how they affect phenotype prediction.

Gene expression

Gene expression measurement methods have three main categories. The first to be created is the gene expression microarray. In a microarray, RNA is reverse transcribed to cDNA, labeled with fluorescent markers, then hybridized to probes corresponding to parts of genes. The amount of fluorescence is then quantified to give the relative amount of gene expression for each gene. While early microarrays had fewer genes and gene probes [11], more modern ones measure tens of thousands of genes [12].

While microarrays are useful, decreases in the price of genetic sequencing have made bulk RNA sequencing (RNA-seq) more common. In RNA-seq, cDNA molecules are sequenced directly after being reverse transcribed from mRNA. These cDNA fragments are then aligned against a reference exome to determine which gene, if any, each fragment maps to. The output of the bulk RNA-seq pipeline is a list of genes and their corresponding read counts. While there is not gene probe bias like in microarrays, RNA-seq has its own patterns of bias based on gene lengths and expression levels [13]. Bulk RNA-seq is also unable to resolve heterogeneous populations of cells, as it measures the average gene expression of all of cells in the sample.

Fairly recently a new method was developed called single-cell RNA sequencing. True to its name, single-cell sequencing allows gene expression to be measured at the individual cell level. This increase in precision is accompanied by an increase in data sparsity though, as genes expressed infrequently or at low levels may not be detected. The sparsity of single-cell data has led to a number of interesting methods, but as we worked with bulk RNA-sequencing single-cell papers will largely be absent from this review.

Machine Learning

Machine learning has undergone a paradigm shift in the past decade, beginning with the publication of the AlexNet paper in 2012 [14]. For decades random forests and support vector machines were the most widely used models in machine learning. This changed dramatically when the AlexNet paper showed that neural networks could vastly outperform traditional methods in some domains [14]. The deep learning revolution quickly followed, with deep neural networks becoming the state of the art in any problem with enough data [15,16,17,18].

The implications of the deep learning revolution on this paper are twofold. First, almost all papers before 2014 use traditional machine learning methods, while almost all papers after use deep learning methods. Second, deep neural networks' capacity to overfit the data and fail to generalize to outside data are vast. We'll show throughout the review various mistakes authors make because they don't fully understand the failure states of neural networks and how to avoid them.

Dimensionality Reduction

The most obvious challenge in working with gene expression data is its high dimensionality. That is to say that the number of features (genes) in a dataset is typically greater than the number of samples. It is common for an analysis to have tens of thousands of genes, but only hundreds (or tens) of samples. Because even simple models struggle under such circumstances, it is necessary to find a representation of the data that uses fewer dimensions.

In the traditional machine learning paradigm, this is done via manual or heuristic feature selection methods. Such methods tend to use a criterion like mutual information to select a subset of genes for the analysis [19]. In one of the earliest papers in this review, Li et al. try a eight different methods from statistics and machine learning to see if any one in particular outperformed the others [20]. Ultimately they found that no individual method rose to the top, and that the performance of different methods varies depending on the problem.

A number of other papers since then have also used manual methods. Grewal et al. chose a subset of genes from COSMIC [21] for training, but found that their model performed better when using all genes instead of just a subset [22]. Chen et al. used a different gene set. They selected the LINCS 1000 gene set [23] for an imputation method, as the LINCS landmark genes are highly correlated with the genes they were trying to impute [24].

Gene subsets can be based on prior knowledge of gene regulatory networks as well [25,26]. While very interpretable, these methods do not necessarily lead to increased performance in phenotype predictions [27]. However, such methods can be useful in their own right. PLIER (and the associated MultiPLIER framework) use prior knowledge genes to guide the latent variables learned by a matrix factorization technique [28,29]. The resulting latent variables can then be used in differential expression analyses in lieu of raw gene counts, allowing dimensionality reduction while guiding the learned variables towards biological relevance.

Selecting gene subsets via a heuristic or a machine learning model is also popular. Sevakula et al. use decision stumps to select features then use a stacked autoencoder-type architecture to further compress the representation [30]. Xiao et al. did something similar where they reduced the data to only genes were differentially expressed between their conditions of interest, then used a stacked autoencoder architecture [31]. Instead of looking at raw differential expression, Dhruba et al. used another subsetting method called ReliefF [32] to find the top 200 genes for their source and target dataset, then kept the intersection for use in their model [33]. More recently, Li et al. used a genetic algorithm for feature selection [34].

Not all papers use a subset of the original genes in their analysis, however. It is fairly common in recent years for authors to transform the data into a new lower dimensional space based on various metrics. This used to be done via principle component analysis (PCA), a method that performs a linear transformation to maximize the variance explained by a reduced number of dimensions [35,36]. Now scientists typically use different types of autoencoders, which learn a nonlinear mapping from the original space to a space with fewer dimensions. DeepPathology uses variational [37] and contractive [38] autoencoders in their model [39], while Danaee et al. used a stacked denoising autoencoder [40,41]. Both papers compared their autoencoder dimensionality reduction to that of PCA and found that it performed better. Danaee found that kernel PCA, a nonlinear version of PCA performed equivalently though.

It is also possible to use regularization methods to perform dimensionality reduction. While they do not influence the nominal dimensionality of the data, they reduce the effective dimensionality by putting constraints on the input data or the model. For example, SAUCIE uses an autoencoder structure, but combines it with a number of exotic regularization methods to further decrease the effective dimensionality of their data [42]. In DeepType, Chen et al. use a more conventional elastic net regularization [43] to induce sparsity in the first level of their network under the assumption that most genes' expression will not affect a cancer's subtype [4].

Ultimately, there is no clear consensus in which dimensionality reduction methods perform the best. Among the methods that transform the data there is a small amount of evidence that nonlinear transformations outperform linear ones, but only a few studies have tried both. Going forward, a

systematic evaluation of gene selection and dimensionality reduction methods on a variety of problems could be a huge asset to the field.

Batch Effects

When gene expression data comes from multiple studies, there are systematic differences between the samples even if they are measuring the same thing [44]. These batch effects can bias the outcome of a study, and reduce the ability of a predictive model to generalize to data outside of the dataset used in the analysis. Different studies handle this in different ways, with varying degrees of effectiveness.

Malta et al's study is a good example of addressing batch effects well [45]. They began by mean centering their data to ensure that the model didn't learn to make classifications based on the mean gene expression values. They then used Spearman correlation instead of Pearson correlation to avoid small changes in the data distributions to change their correlation measurement. Finally they evaluated their results on a different data generation method (RNA-seq) from the one they trained on (microarray).

The SAUCIE paper handles batch effects very differently [42]. They introduce a new type of regularization called maximal mean discrepancy, which penalizes the distance between the latent space representation between batches. While this regularization term is deep learning specific and depends on the model having an embedding layer, it will be interesting to see if similar ideas are used in the future.

Other studies address batch effects less comprehensively via quantile normalization and 0-1 standardization [24,46]. Using quantile normalization ensures that the different datasets have the same distribution, then 0-1 standardization makes machine learning algorithms treat all genes as equally important. Another common technique from ML is to make decisions about the model based on cross-validation. Since the feature or hyperparameter choice is validated on multiple random subsets of the data, batch effects are less likely to bias the decision [34].

Studies using contractive autoencoders [39] get some degree of batch effect protection just from their model constraints. Since contractive autoencoders are trained to ignore small perturbations in the data, they tend to be more robust to distributional changes. There are also more explicit ways of addressing batch effects. DeepType, for example, uses the method ComBat [47] to reduce batch effects as a preprocessing step for their model [4].

Unfortunately many studies don't address batch effects at all, despite operating on large multi-study datasets like the Cancer Genome Atlas (TCGA). These studies are likely to fail to generalize to real-world data, as machine learning models like to fixate on spurious correlations between data and phenotypes.

Deep Learning vs Standard ML As was discussed in the background section, recent years have seen a dramatic shift towards deep learning methods. It is not immediately clear, however, whether this is a good decision for problems without giant datasets. While some argue that deep learning is overrated and simpler models should be used instead [48,49], others find that deep learning outperforms even domain specific models [50,51].

Because it is unclear which type of model will perform best on which dataset, it is important to try both simple and complex models. In the Deep pathology paper, Azarkahlili et al. found that their deep neural networks outperformed decision tree, KNN, random forest, logistic regression, and SVM models [39]. Likewise, in gene expression imputation, Chen et al. found that their neural network classifier outperformed linear regression in 99.97 percent of genes and k-nearest neighbors in all

genes [24]. On the other hand, Grewal et al. tried multiple methods and found they work roughly the same [22]. They settled this by combining a few different models into an ensemble.

Due to technical considerations [45] or other reasons, some authors only evaluate a single model [31]. While this simplifies the analysis for their papers, it makes it unclear whether they could have done better with a different model. This is particularly important for authors who are using deep learning models, because simpler models tend to be much more interpretable.

Evaluating Model Performance

Validation is another important consideration in phenotype prediction. The gold standard of validation would be a knockout and rescue assay demonstrating that the predicted mechanism or expression relationship truly exists. Since machine learning models make predictions of nonlinear relationships between thousands of genes, however, such validation isn't feasible. Instead scientists evaluate their models' efficacy by testing their performance on data they didn't train them on. Test datasets can be built in different ways, assorting roughly into three tiers based on their external validity.

The most basic method is referred to as cross-validation. In cross-validation, the training data is split into a training and validation dataset. The model is trained on the training dataset, then its performance is measured on the validation dataset. Typically this is done with a process called five-fold cross-validation, where the process is repeated five times on five different ways of splitting up the training data. This method is common [33,34,41], but isn't really a rigorous evaluation. Because the same dataset is used for both selecting a model and measuring performance, the data can 'go stale' when you test several models [52]. In the extreme case, it is possible to get 100% accuracy by testing random prediction schemes on the data.

In order to keep data fresh, some researchers use a more rigorous method called a held out test set [30,39]. In the held out test set paradigm, a portion of the dataset is set aside and effectively put in a locked box until the end of the analysis. Once the model architecture, hyperparameters, and dimensionality reduction decisions are all made via cross-validation on the training data, the lock box can be opened and the data within used for evaluation. As the lock box data is only used once, it has no risk of becoming stale due to multiple testing. The only drawback to this method is that it depends on the assumption that the data in the real world is distributed the same as the data in your training set.

The best (and most difficult) way to evaluate a model is by using an independent dataset. Ideally, an independent dataset is created by a different group or on a different expression quantification platform. For example, once their model was trained, Chen et al. evaluated their model on a dataset from GEO, a dataset from GTEx, and a cancer cell line [24]. It is also possible to use combinations of validation methods. In their paper Grewal et al. used a held-out section of their original data, then went on to evaluate their model in an independent dataset [22]. Similarly, Malta et al. used cross-validation initially, but then evaluated their model on an external microarray dataset to ensure their data wasn't stale [45]. Likewise, Deng et al. initially benchmark their model on various simulated data sets, but then go on to validate their model on real data [53].

Ultimately researchers work with what they have, and it's not always possible to acquire an independent dataset. That being said, it is always worth keeping the different tiers of external validity in mind when evaluating papers that use machine learning.

Transfer Learning

Transfer learning is a field of machine learning that uses information from outside of the training dataset to improve model performance. Techniques from the field of transfer learning are particularly useful in the domain of gene expression, because there are large databases like GEO and TCGA that

contain data that may be useful in prediction tasks. In this section we'll focus in on two types of transfer learning that are particularly useful: multitask learning and semi-supervised learning.

Multitask learning involves training a model on multiple problems in order to improve the model's performance on a problem of interest. As gene expression patterns can be shared across diseases [54,55], the extra data can help increase the model's power. For example, instead of training a model to learn one drug response at a time, Yuan et al. had better results predicting all the drugs in their dataset simultaneously [56]. Similarly, Deepathology predicts tissue type, disease, and miRNA expression simultaneously [39]. It is worth noting that multitask learning works best when using a deep learning model. When using standard machine learning it is necessary to perform some difficult data transformation to do classification on multiple classes [20].

Where supervised learning uses entirely labeled data, semi-supervised learning takes advantage of unlabeled data as well. The most popular way of doing semi-supervised learning is to use an autoencoder structure to initialize your model's weights. Where most models begin training with a randomly initialized set of weights, it is possible to initially train a neural network to create a compressed representation of the input data (an encoding). The weights that it learns in the process often turn out to be a better initialization when the labeled training data is finally brought in. There are a number of ways to perform the autoencoding step. Instead of training all the layers of the network simultaneously, it is possible to train one layer to create the encoding at a time [30,31]. This is referred to as a stacked autoencoder. One can also train the whole network at the same time, as Danaee et al do with their denoising autoencoder [41]. Not all methods are autoencoder-based though. Dhruva et al. develop their own semi-supervised learning process that teaches a model to learn a latent space between classes [33].

Future Directions

Upon reviewing a broad spectrum of what has been done in the field, a few opportunities for future research have become clear.

As shown in the batch effects section, authors handle batch effects in their studies with varying degrees of sophistication. The studies we have discussed use various strategies to mitigate the technical variation between studies and batches, but it may be possible to do better. Recent developments in the field of transfer learning have lead to methods that use technical variation between samples to increase the power of an analysis [57,58]. These methods exist on the bleeding edge of transfer learning, but gene expression data fits their assumptions very well. It would be interesting to see if models trained with such methods would be more successful than those using traditional batch effect correction.

While many models have been used to make predictions from gene expression, it's unclear which ones work best, and in which circumstances. One review evaluated a variety of unsupervised methods on gene regulatory network discovery, but the only supervised method that was tried was a support vector machine [59]. A large scale study comparing methods to each other would be very useful to the field. Of particular interest would be a study that determines roughly how many samples are needed before it deep learning models outperform traditional machine learning models, and how semi-supervised learning shifts that change point.

Semi-supervised learning is a technique that began being applied to gene expression data only recently. While the technique has been useful when applied to large amounts of unlabeled data, the effects of which unlabeled dataset(s) are used hasn't been measured. Due to the large differences between RNA-seq and microarray data, it may make sense to do pretraining with just GEO or Recount3 [60] depending on whether the labeled data is primarily from microarrays or RNA-seq. A study looking at whether more data is always better, and whether using data from a different

platform helps or hurts would be a useful reference for those using semi-supervised learning to train their models.

Looking closer at how to do multitask learning could also help the field. While several studies in this review have analyzed multitask learning, there is not a study that we know of that determines exactly how similar the classes should be for gene expression data. Testing various methods from Sebastian Ruder's multitask learning review paper could help find a heuristic for how similar phenotypes should be in multitask learning [\[61\]](#).

For the most part the studies in this review either learn how to diagnose a specific phenotype with a small dataset, or learn more classes by studying TCGA data. We believe that there is an opportunity for datasets to be created from Recount3 and Refine.bio [\[60,62\]](#) data that would be able to predict phenotypes other than just cancer on a large dataset. The consistent preprocessing for these resources makes their gene expression data much easier to use with machine learning methods.

Conclusion and Perspectives

Making predictions from gene expression information holds great promise, and is already being used in some cases. Because the problem space lies between the fields of machine learning and computational biology, however, it inherits pitfalls from both fields. Frequently, biologists who want to attempt to make models will fail to understand how to do model validation and hyperparameter tuning in a way that doesn't invalidate their results. Likewise, machine learning researchers often will leak information between the training and the testing set by blindly randomizing all their samples, or will fail to account for the batch effects inherent to multi-study datasets.

In addition to the challenges from working across disciplines, the approaches used in making predictions are largely fragmented. Researchers make decisions about their model architecture, dimensionality reduction, and batch effect correction largely based on their intuition. There have been few papers evaluating methods across several problems, and even less consensus about which methods work the best. Moving forward, the field will need to consolidate and determine a set of best practices to reduce the model search space for new papers. Likewise, researchers will need to begin working with clinicians and wet-lab scientists to validate whether their models work in vivo as well as in-silico. Ultimately, phenotype predictions from gene expression appear to have a bright future. In order to get there, however, there are many challenges that need to be addressed.

Reproducible research background

Citation indices background

Talk briefly about conclusion chapter (probably write this part once it's done)

Citation index review

Over the past century quantifying the progress of science has become popular. Even before computers made it easy to collate information about publications, work had already begun to evaluate papers based on their number of citations [\[63\]](#). There's even a book about it [\[64\]](#).

Determining the relative "impact" of different authors and journals is a perennial question when measuring science. One of the most commonly used metric in this space is the h-index, which balances an authors quantity of publications with the number of citations each one receives [\[65\]](#). However, the h-index is not a perfect metric [\[66\]](#), and has arguably become less useful in recent years

[67]. Other metrics, like the g-index[68] and the i-10 index (<https://scholar.google.com/>), try to improve on the h-index by placing a higher weight on more highly cited papers.

There are metrics for comparing journals as well. The Journal Impact Factor [69] is the progenitor journal metric, evaluating journals based on how many citations the average paper in that journal has received over the past few years. Other measures use a more network-based approach to quantifying journals' importance. The most common are Eigenfactor and the SCImago Journal Rank, which use variations on the PageRank algorithm to evaluate the importance of various journals [70,71/]

Academic articles are arguably the main building blocks of scientific communication, so it makes sense to try to better understand which ones are the most important. Citation count seems like an obvious choice, but differences in citation practices between fields [72] make it too crude a measure of impact. Instead, many other metrics have been developed to choose which papers to read.

Many of these methods work by analyzing the graph formed by treating articles as nodes and citations as edges. PageRank[73/], one of the most influential methods for ranking nodes' importance in a graph, can also be applied to ranking papers [74]. It isn't the only graph-based method though. Other methods of centrality such as betweenness centrality would make sense to use, but are prohibitively computationally expensive to run. Instead, methods like the disruption index [75] and its variants [76] are more often used.

Some lines of research try to quantify other desirable characteristics of papers. For example, Foster et al. claim to measure innovation by looking at papers that create new connections between known chemical entities [77]. Likewise, Wang et al. define novel papers as those that cite papers from unusual combinations of journals [78]. The Altmetric Attention Score (<https://www.altmetric.com/>) goes even further, measuring the attention on a paper from outside the standard academic channels.

These metrics don't stand alone, however. Lots of work has gone into improving the various methods by shoring up their weaknesses or normalizing them to make them more comparable across fields. The relative citation ratio makes citation counts comparable across fields by normalizing it according to other papers in its neighborhood of the citation network [79]. Similarly, the source-normalized impact per paper normalizes the citation count for based on the total number of citations in the whole field [80]. Several methods modify PageRank, such as Topical PageRank, which incorporates topic and journal prestige information to the PageRank calculation [81], and Vaccario et al's page and field rescaled PageRank which accounts for differences between papers' ages and fields [82]. There are also a number of variants of the disruption index [76].

Of course, none of these methods would be possible without data to train and evaluate them on. We've come a long way from Garfield's "not unreasonable" proposal to manually aggregate one million citations [63]. These days we have several datasets with hundreds of millions to billions of references [83,84,85].

Quantifying science isn't perfect, however. In addition to shortcomings of individual methods [86,87,88], there are issues inherent to reducing the process of science to numbers. To quote Alfred Korzybski, "the map is not the territory." Metrics of science truly measure quantitative relationships like mean citation counts, despite purporting to reflect "impact", "disruption", or "novelty". If we forget that, we can mistake useful tools for arbiters of ground truth.

In chapter X, we dive into one such shortcoming, by demonstrating differences in article PageRanks between fields. There we argue that normalizing out field-specific differences obscures useful signal, and propose new directions of research for future citation metrics.

Reproducibility intro

What is computational reproducibility

Reproducibility is a topic often discussed in scientific circles, and it means different things to different people [89,90,91,92,93,94]. For the sake of clarity, we'll operate from Stodden et al's definition "the ability to recreate computational results from the data and code used by the original researcher" (http://stodden.net/icerm_report.pdf). We would like to add one caveat though. The language surrounding reproducibility is often binary, as in "reproducible research" or "an irreproducible paper". In reality, reproducibility falls on a sliding scale based on how long it takes a scientist to reproduce a work. For poorly specified work, it could take forever as the conditions that allowed the research will never happen again. For extremely high quality research, it could take a scientist only seconds of their time to press the "run" button on the original authors' code and get the same results.

Why does it matter?

Now that we've defined what reproducibility is, we can discuss why it matters. In her book "Why Trust Science?", Naomi Oreskes argues the answer to the eponymous question is that the process of coming to a consensus is what makes science trustworthy [95]. In a world where all papers take forever to reproduce, it would be challenging to come to the consensus required to do trustworthy science.

Another way of viewing the scientific method is the Popperian idea of falsifiable theories [96]. Theories are constructed from evidence and from reproduction of the same findings about the world. If a theory can't be reproduced, then it can't be supported or proven false, and isn't science under Popper's definition [97].

Those points are fairly philosophical though. If you're looking for a discussion of concrete impacts of failures in computational reproducibility, we recommend Ivie and Thain's review paper [98]. They point out that in the biological domain preclinical drug development studies could be replicated in only 10-25% of cases [99,100]. Similarly, only about 50% of ACM papers were able to be built from their source code (<http://repeatability.cs.arizona.edu/v2/RepeatabilityTR.pdf>) In general, lack of reproducibility could cause a lack of trust in science [101]

Reproducibility isn't all about preventing bad things from happening though. Having code that is easy to run helps verify that code is bug-free, and makes it easier for the original author to run in the future. It also allows remixing research code, leading to greater accessibility of scientific research. Because the authors working on latent diffusion models for image synthesis made their code available, others quickly created an optimized version allowing those without a powerful GPU to run it [[102]; <https://github.com/CompVis/stable-diffusion>; <https://github.com/basujindal/stable-diffusion/>]

What can be done?

Document well, write code for ease of executability, and make code deterministic [103]

Maybe we should create a central repository of data and code used in research like we have a repository for articles in PubMed Central [104]. The field of machine learning has something similar in Papers with Code (<https://paperswithcode.com/>), a website where you can browse only the machine learning preprints and papers that have associated code.

Executable papers (CITE distil.pub, ELife)

In chapter X, we give our own recommendations for ways to make machine learning research in the life sciences reproducible.

References

1. **Machine learning approaches to predict lupus disease activity from gene expression data**
Brian Kegerreis, Michelle D Catalina, Prathyusha Bachali, Nicholas S Geraci, Adam C Labonte, Chen Zeng, Nathaniel Stearrett, Keith A Crandall, Peter E Lipsky, Amrie C Grammer
Scientific Reports (2019-07-03) <https://doi.org/gh33ng>
DOI: [10.1038/s41598-019-45989-0](https://doi.org/10.1038/s41598-019-45989-0) · PMID: [31270349](https://pubmed.ncbi.nlm.nih.gov/31270349/) · PMCID: [PMC6610624](https://pubmed.ncbi.nlm.nih.gov/PMC6610624/)
2. **Weighted elastic net for unsupervised domain adaptation with application to age prediction from DNA methylation data**
Lisa Handl, Adrin Jalali, Michael Scherer, Ralf Eggeling, Nico Pfeifer
Bioinformatics (2019-07) <https://doi.org/gf5d8b>
DOI: [10.1093/bioinformatics/btz338](https://doi.org/10.1093/bioinformatics/btz338) · PMID: [31510704](https://pubmed.ncbi.nlm.nih.gov/31510704/) · PMCID: [PMC6612879](https://pubmed.ncbi.nlm.nih.gov/PMC6612879/)
3. **UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction**
Leland McInnes, John Healy, James Melville
arXiv (2018) <https://doi.org/gqzqzn>
DOI: [10.48550/arxiv.1802.03426](https://doi.org/10.48550/arxiv.1802.03426)
4. **Deep-learning approach to identifying cancer subtypes using high-dimensional genomic data**
Runpu Chen, Le Yang, Steve Goodison, Yijun Sun
Bioinformatics (2019-10-11) <https://doi.org/gpfzxm>
DOI: [10.1093/bioinformatics/btz769](https://doi.org/10.1093/bioinformatics/btz769) · PMID: [31603461](https://pubmed.ncbi.nlm.nih.gov/31603461/) · PMCID: [PMC8215925](https://pubmed.ncbi.nlm.nih.gov/PMC8215925/)
5. **Applications of liquid biopsies for cancer**
Austin K Mattox, Chetan Bettgowda, Shibin Zhou, Nickolas Papadopoulos, Kenneth W Kinzler, Bert Vogelstein
Science Translational Medicine (2019-08-28) <https://doi.org/gjsfw9>
DOI: [10.1126/scitranslmed.aay1984](https://doi.org/10.1126/scitranslmed.aay1984) · PMID: [31462507](https://pubmed.ncbi.nlm.nih.gov/31462507/)
6. **Histopathologic variables predict Oncotype DX™ Recurrence Score**
Melina B Flanagan, David J Dabbs, Adam M Brufsky, Sushil Beriwal, Rohit Bhargava
Modern Pathology (2008-03-21) <https://doi.org/d27rv3>
DOI: [10.1038/modpathol.2008.54](https://doi.org/10.1038/modpathol.2008.54) · PMID: [18360352](https://pubmed.ncbi.nlm.nih.gov/18360352/)
7. **Analysis of blood-based gene expression in idiopathic Parkinson disease**
Ron Shamir, Christine Klein, David Amar, Eva-Juliane Vollstedt, Michael Bonin, Marija Usenovic, Yvette C Wong, Ales Maver, Sven Poths, Hershel Safer, ... Dimitri Krainc
Neurology (2017-09-15) <https://doi.org/gcnb67>
DOI: [10.1212/wnl.0000000000004516](https://doi.org/10.1212/wnl.0000000000004516) · PMID: [28916538](https://pubmed.ncbi.nlm.nih.gov/28916538/) · PMCID: [PMC5644465](https://pubmed.ncbi.nlm.nih.gov/PMC5644465/)
8. **Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifer Evaluation**
Nicholas D Walter, Mikaela A Miller, Joshua Vasquez, Marc Weiner, Adam Chapman, Melissa Engle, Michael Higgins, Amy M Quinones, Vanessa Rosselli, Elizabeth Canono, ... Mark W Geraci
Journal of Clinical Microbiology (2016-02) <https://doi.org/gqzq2r>
DOI: [10.1128/jcm.01990-15](https://doi.org/10.1128/jcm.01990-15) · PMID: [26582831](https://pubmed.ncbi.nlm.nih.gov/26582831/) · PMCID: [PMC4733166](https://pubmed.ncbi.nlm.nih.gov/PMC4733166/)
9. **A Transcriptomic Biomarker to Quantify Systemic Inflammation in Sepsis — A Prospective Multicenter Phase II Diagnostic Study**
Michael Bauer, Evangelos J Giamarellos-Bourboulis, Andreas Kortgen, Eva Möller, Karen Felsmann, Jean Marc Cavaillon, Orlando Guntinas-Lichius, Olivier Rutschmann, Andriy Ruryk, Matthias Kohl, ... Konrad Reinhart

EBioMedicine (2016-04) <https://doi.org/gqzq2q>
DOI: [10.1016/j.ebiom.2016.03.006](https://doi.org/10.1016/j.ebiom.2016.03.006) · PMID: [27211554](https://pubmed.ncbi.nlm.nih.gov/27211554/) · PMCID: [PMC4856796](https://pubmed.ncbi.nlm.nih.gov/PMC4856796/)

10. **Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome**
Ndate Fall, Michael Barnes, Sherry Thornton, Lorie Luyrink, Judyann Olson, Norman T Ilowite, Beth S Gottlieb, Thomas Griffin, David D Sherry, Susan Thompson, ... Alexei A Grom
Arthritis & Rheumatism (2007) <https://doi.org/chxcfh>
DOI: [10.1002/art.22981](https://doi.org/10.1002/art.22981) · PMID: [17968951](https://pubmed.ncbi.nlm.nih.gov/17968951/)
11. **Light-Directed, Spatially Addressable Parallel Chemical Synthesis**
Stephen PA Fodor, JLeighton Read, Michael C Pirrung, Lubert Stryer, Amy Tsai Lu, Dennis Solas
Science (1991-02-15) <https://doi.org/dw6f5b>
DOI: [10.1126/science.1990438](https://doi.org/10.1126/science.1990438) · PMID: [1990438](https://pubmed.ncbi.nlm.nih.gov/1990438/)
12. **Expression monitoring by hybridization to high-density oligonucleotide arrays**
David J Lockhart, Helin Dong, Michael C Byrne, Maximillian T Follettie, Michael V Gallo, Mark S Chee, Michael Mittmann, Chunwei Wang, Michiko Kobayashi, Heidi Norton, Eugene L Brown
Nature Biotechnology (1996-12) <https://doi.org/bpmwzt>
DOI: [10.1038/nbt1296-1675](https://doi.org/10.1038/nbt1296-1675) · PMID: [9634850](https://pubmed.ncbi.nlm.nih.gov/9634850/)
13. **Comparison of RNA-Seq and Microarray in Transcriptome Profiling of Activated T Cells**
Shanrong Zhao, Wai-Ping Fung-Leung, Anton Bittner, Karen Ngo, Xuejun Liu
PLoS ONE (2014-01-16) <https://doi.org/f5tvq3>
DOI: [10.1371/journal.pone.0078644](https://doi.org/10.1371/journal.pone.0078644) · PMID: [24454679](https://pubmed.ncbi.nlm.nih.gov/24454679/) · PMCID: [PMC3894192](https://pubmed.ncbi.nlm.nih.gov/PMC3894192/)
14. **ImageNet classification with deep convolutional neural networks**
Alex Krizhevsky, Ilya Sutskever, Geoffrey E Hinton
Communications of the ACM (2017-05-24) <https://doi.org/gbhxhs>
DOI: [10.1145/3065386](https://doi.org/10.1145/3065386)
15. **Understanding Back-Translation at Scale**
Sergey Edunov, Myle Ott, Michael Auli, David Grangier
arXiv (2018) <https://doi.org/gqzq2v>
DOI: [10.48550/arxiv.1808.09381](https://doi.org/10.48550/arxiv.1808.09381)
16. **Exploring the Limits of Transfer Learning with a Unified Text-to-Text Transformer**
Colin Raffel, Noam Shazeer, Adam Roberts, Katherine Lee, Sharan Narang, Michael Matena, Yanqi Zhou, Wei Li, Peter J. Liu
arXiv (2019-10-23) <https://arxiv.org/abs/1910.10683v3>
17. **U-Net: Convolutional Networks for Biomedical Image Segmentation**
Olaf Ronneberger, Philipp Fischer, Thomas Brox
arXiv (2015-05-19) <https://arxiv.org/abs/1505.04597>
18. **Highly accurate protein structure prediction with AlphaFold**
John Jumper, Richard Evans, Alexander Pritzel, Tim Green, Michael Figurnov, Olaf Ronneberger, Kathryn Tunyasuvunakool, Russ Bates, Augustin Žídek, Anna Potapenko, ... Demis Hassabis
Nature (2021-07-15) <https://doi.org/gk7nfp>
DOI: [10.1038/s41586-021-03819-2](https://doi.org/10.1038/s41586-021-03819-2) · PMID: [34265844](https://pubmed.ncbi.nlm.nih.gov/34265844/) · PMCID: [PMC8371605](https://pubmed.ncbi.nlm.nih.gov/PMC8371605/)
19. **A review of feature selection methods based on mutual information**
Jorge R Vergara, Pablo A Estévez
Neural Computing and Applications (2013-03-13) <https://doi.org/gj7fzd>
DOI: [10.1007/s00521-013-1368-0](https://doi.org/10.1007/s00521-013-1368-0)

20. **A comparative study of feature selection and multiclass classification methods for tissue classification based on gene expression**
T Li, C Zhang, M Ogihara
Bioinformatics (2004-04-15) <https://doi.org/b3kzzp>
DOI: [10.1093/bioinformatics/bth267](https://doi.org/10.1093/bioinformatics/bth267) · PMID: [15087314](https://pubmed.ncbi.nlm.nih.gov/15087314/)
21. **COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer**
Simon A Forbes, Gurpreet Tang, Nidhi Bindal, Sally Bamford, Elisabeth Dawson, Charlotte Cole, Chai Yin Kok, Mingming Jia, Rebecca Ewing, Andrew Menzies, ... PAndrew Futreal
Nucleic Acids Research (2009-11-10) <https://doi.org/fhkk8s>
DOI: [10.1093/nar/gkp995](https://doi.org/10.1093/nar/gkp995) · PMID: [19906727](https://pubmed.ncbi.nlm.nih.gov/19906727/) · PMCID: [PMC2808858](https://pubmed.ncbi.nlm.nih.gov/PMC2808858/)
22. **Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers**
Jasleen K Grewal, Basile Tessier-Cloutier, Martin Jones, Sitanshu Gakkhar, Yussanne Ma, Richard Moore, Andrew J Mungall, Yongjun Zhao, Michael D Taylor, Karen Gelmon, ... Steven JM Jones
JAMA Network Open (2019-04-26) <https://doi.org/gf84h2>
DOI: [10.1001/jamanetworkopen.2019.2597](https://doi.org/10.1001/jamanetworkopen.2019.2597) · PMID: [31026023](https://pubmed.ncbi.nlm.nih.gov/31026023/) · PMCID: [PMC6487574](https://pubmed.ncbi.nlm.nih.gov/PMC6487574/)
23. **A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles**
Aravind Subramanian, Rajiv Narayan, Steven M Corsello, David D Peck, Ted E Natoli, Xiaodong Lu, Joshua Gould, John F Davis, Andrew A Tubelli, Jacob K Asiedu, ... Todd R Golub
Cell (2017-11) <https://doi.org/cgwt>
DOI: [10.1016/j.cell.2017.10.049](https://doi.org/10.1016/j.cell.2017.10.049) · PMID: [29195078](https://pubmed.ncbi.nlm.nih.gov/29195078/) · PMCID: [PMC5990023](https://pubmed.ncbi.nlm.nih.gov/PMC5990023/)
24. **Gene expression inference with deep learning**
Yifei Chen, Yi Li, Rajiv Narayan, Aravind Subramanian, Xiaohui Xie
Bioinformatics (2016-02-11) <https://doi.org/f8vmtt>
DOI: [10.1093/bioinformatics/btw074](https://doi.org/10.1093/bioinformatics/btw074) · PMID: [26873929](https://pubmed.ncbi.nlm.nih.gov/26873929/) · PMCID: [PMC4908320](https://pubmed.ncbi.nlm.nih.gov/PMC4908320/)
25. **Robust clinical outcome prediction based on Bayesian analysis of transcriptional profiles and prior causal networks**
Kourosh Zarringhalam, Ahmed Enayetallah, Padmalatha Reddy, Daniel Ziemek
Bioinformatics (2014-06-11) <https://doi.org/f58bp2>
DOI: [10.1093/bioinformatics/btu272](https://doi.org/10.1093/bioinformatics/btu272) · PMID: [24932007](https://pubmed.ncbi.nlm.nih.gov/24932007/) · PMCID: [PMC4058945](https://pubmed.ncbi.nlm.nih.gov/PMC4058945/)
26. **Robust phenotype prediction from gene expression data using differential shrinkage of co-regulated genes**
Kourosh Zarringhalam, David Degras, Christoph Brockel, Daniel Ziemek
Scientific Reports (2018-01-19) <https://doi.org/gcwzdn>
DOI: [10.1038/s41598-018-19635-0](https://doi.org/10.1038/s41598-018-19635-0) · PMID: [29352257](https://pubmed.ncbi.nlm.nih.gov/29352257/) · PMCID: [PMC5775343](https://pubmed.ncbi.nlm.nih.gov/PMC5775343/)
27. **Prognostic gene signatures for patient stratification in breast cancer - accuracy, stability and interpretability of gene selection approaches using prior knowledge on protein-protein interactions**
Yupeng Cun, Holger Fröhlich
BMC Bioinformatics (2012-05-01) <https://doi.org/f4cb5r>
DOI: [10.1186/1471-2105-13-69](https://doi.org/10.1186/1471-2105-13-69) · PMID: [22548963](https://pubmed.ncbi.nlm.nih.gov/22548963/) · PMCID: [PMC3436770](https://pubmed.ncbi.nlm.nih.gov/PMC3436770/)
28. **Pathway-level information extractor (PLIER) for gene expression data**
Weiguang Mao, Elena Zaslavsky, Boris M Hartmann, Stuart C Sealfon, Maria Chikina
Nature Methods (2019-06-27) <https://doi.org/gf75g6>
DOI: [10.1038/s41592-019-0456-1](https://doi.org/10.1038/s41592-019-0456-1) · PMID: [31249421](https://pubmed.ncbi.nlm.nih.gov/31249421/) · PMCID: [PMC7262669](https://pubmed.ncbi.nlm.nih.gov/PMC7262669/)

29. **MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease**
Jaclyn N Taroni, Peter C Grayson, Qiwen Hu, Sean Eddy, Matthias Kretzler, Peter A Merkel, Casey S Greene
Cell Systems (2019-05) <https://doi.org/gf75g5>
DOI: [10.1016/j.cels.2019.04.003](https://doi.org/10.1016/j.cels.2019.04.003) · PMID: [31121115](https://pubmed.ncbi.nlm.nih.gov/31121115/) · PMCID: [PMC6538307](https://pubmed.ncbi.nlm.nih.gov/PMC6538307/)
30. **Transfer Learning for Molecular Cancer Classification Using Deep Neural Networks**
Rahul K Sevakula, Vikas Singh, Nishchal K Verma, Chandan Kumar, Yan Cui
IEEE/ACM Transactions on Computational Biology and Bioinformatics (2019-11-01) <https://doi.org/gqzq3p>
DOI: [10.1109/tcbb.2018.2822803](https://doi.org/10.1109/tcbb.2018.2822803) · PMID: [29993662](https://pubmed.ncbi.nlm.nih.gov/29993662/)
31. **A semi-supervised deep learning method based on stacked sparse auto-encoder for cancer prediction using RNA-seq data**
Yawen Xiao, Jun Wu, Zongli Lin, Xiaodong Zhao
Computer Methods and Programs in Biomedicine (2018-11) <https://doi.org/gfnm5c>
DOI: [10.1016/j.cmpb.2018.10.004](https://doi.org/10.1016/j.cmpb.2018.10.004) · PMID: [30415723](https://pubmed.ncbi.nlm.nih.gov/30415723/)
32. Igor Kononenko, Edvard Šimec, Marko Robnik-Šikonja
Applied Intelligence (1997) <https://doi.org/fdm4r3>
DOI: [10.1023/a:1008280620621](https://doi.org/10.1023/a:1008280620621)
33. **Application of transfer learning for cancer drug sensitivity prediction**
Saugato Rahman Dhruba, Raziur Rahman, Kevin Matlock, Souparno Ghosh, Ranadip Pal
BMC Bioinformatics (2018-12) <https://doi.org/gh4mnw>
DOI: [10.1186/s12859-018-2465-y](https://doi.org/10.1186/s12859-018-2465-y) · PMID: [30591023](https://pubmed.ncbi.nlm.nih.gov/30591023/) · PMCID: [PMC6309077](https://pubmed.ncbi.nlm.nih.gov/PMC6309077/)
34. **A comprehensive genomic pan-cancer classification using The Cancer Genome Atlas gene expression data**
Yuanyuan Li, Kai Kang, Juno M Krahn, Nicole Croutwater, Kevin Lee, David M Umbach, Leping Li
BMC Genomics (2017-07-03) <https://doi.org/gfv37q>
DOI: [10.1186/s12864-017-3906-0](https://doi.org/10.1186/s12864-017-3906-0) · PMID: [28673244](https://pubmed.ncbi.nlm.nih.gov/28673244/) · PMCID: [PMC5496318](https://pubmed.ncbi.nlm.nih.gov/PMC5496318/)
35. **Gene expression microarray classification using PCA-BEL**
Ehsan Lotfi, Azita Keshavarz
Computers in Biology and Medicine (2014-11) <https://doi.org/gqzq5p>
DOI: [10.1016/j.combiomed.2014.09.008](https://doi.org/10.1016/j.combiomed.2014.09.008) · PMID: [25282708](https://pubmed.ncbi.nlm.nih.gov/25282708/)
36. <https://www.researchgate.net/publication/281857285> Using deep learning to enhance cancer diagnosis and classification
37. **Auto-Encoding Variational Bayes**
Diederik P Kingma, Max Welling
arXiv (2014-05-02) <https://arxiv.org/abs/1312.6114>
38. **Higher Order Contractive Auto-Encoder**
Salah Rifai, Grégoire Mesnil, Pascal Vincent, Xavier Muller, Yoshua Bengio, Yann Dauphin, Xavier Glorot
Machine Learning and Knowledge Discovery in Databases (2011) <https://doi.org/bfpkgr>
DOI: [10.1007/978-3-642-23783-6_41](https://doi.org/10.1007/978-3-642-23783-6_41)
39. **DeePathology: Deep Multi-Task Learning for Inferring Molecular Pathology from Cancer Transcriptome**
Behrooz Azarkhalili, Ali Saberi, Hamidreza Chitsaz, Ali Sharifi-Zarchi
Scientific Reports (2019-11-11) <https://doi.org/gpg7vc>

DOI: [10.1038/s41598-019-52937-5](https://doi.org/10.1038/s41598-019-52937-5) · PMID: [31712594](https://pubmed.ncbi.nlm.nih.gov/31712594/) · PMCID: [PMC6848155](https://pubmed.ncbi.nlm.nih.gov/PMC6848155/)

40. **Stacked Denoising Autoencoders: Learning Useful Representations in a Deep Network with a Local Denoising Criterion**
Pascal Vincent, Hugo Larochelle, Isabelle Lajoie, Yoshua Bengio, Pierre-Antoine Manzagol
Journal of Machine Learning Research (2010) <http://jmlr.org/papers/v11/vincent10a.html>
41. **A DEEP LEARNING APPROACH FOR CANCER DETECTION AND RELEVANT GENE IDENTIFICATION**
PADIDEH DANAEE, REZA GHAEINI, DAVID A HENDRIX
Biocomputing 2017 (2016-11-22) <https://doi.org/ggqzq5q>
DOI: [10.1142/9789813207813_0022](https://doi.org/10.1142/9789813207813_0022) · PMID: [27896977](https://pubmed.ncbi.nlm.nih.gov/27896977/) · PMCID: [PMC5177447](https://pubmed.ncbi.nlm.nih.gov/PMC5177447/)
42. **Exploring single-cell data with deep multitasking neural networks**
Matthew Amodio, David van Dijk, Krishnan Srinivasan, William S Chen, Hussein Mohsen, Kevin R Moon, Allison Campbell, Yujiao Zhao, Xiaomei Wang, Manjunatha Venkataswamy, ... Smita Krishnaswamy
Nature Methods (2019-10-07) <https://doi.org/gf9rsg>
DOI: [10.1038/s41592-019-0576-7](https://doi.org/10.1038/s41592-019-0576-7) · PMID: [31591579](https://pubmed.ncbi.nlm.nih.gov/31591579/)
43. <https://www.jstor.org/stable/3647580>
44. **Detecting and correcting systematic variation in large-scale RNA sequencing data**
Sheng Li, Paweł P Łabaj, Paul Zumbo, Peter Sykacek, Wei Shi, Leming Shi, John Phan, Po-Yen Wu, May Wang, Charles Wang, ... Christopher E Mason
Nature Biotechnology (2014-08-24) <https://doi.org/f6j2gj>
DOI: [10.1038/nbt.3000](https://doi.org/10.1038/nbt.3000) · PMID: [25150837](https://pubmed.ncbi.nlm.nih.gov/25150837/) · PMCID: [PMC4160374](https://pubmed.ncbi.nlm.nih.gov/PMC4160374/)
45. **Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation**
Tathiane M Malta, Artem Sokolov, Andrew J Gentles, Tomasz Burzykowski, Laila Poisson, John N Weinstein, Bożena Kamińska, Joerg Huelsken, Larsson Omberg, Olivier Gevaert, ... Armaz Mariamidze
Cell (2018-04) <https://doi.org/gc93hh>
DOI: [10.1016/j.cell.2018.03.034](https://doi.org/10.1016/j.cell.2018.03.034) · PMID: [29625051](https://pubmed.ncbi.nlm.nih.gov/29625051/) · PMCID: [PMC5902191](https://pubmed.ncbi.nlm.nih.gov/PMC5902191/)
46. **<p>The blood transcriptional signature for active and latent tuberculosis</p>**
Min Deng, Xiao-Dong Lv, Zhi-Xian Fang, Xin-Sheng Xie, Wen-Yu Chen
Infection and Drug Resistance (2019-01) <https://doi.org/gqzq6v>
DOI: [10.2147/idr.s184640](https://doi.org/10.2147/idr.s184640) · PMID: [30787624](https://pubmed.ncbi.nlm.nih.gov/30787624/) · PMCID: [PMC6363485](https://pubmed.ncbi.nlm.nih.gov/PMC6363485/)
47. **Adjusting batch effects in microarray expression data using empirical Bayes methods**
WEvan Johnson, Cheng Li, Ariel Rabinovic
Biostatistics (2006-04-21) <https://doi.org/dsf386>
DOI: [10.1093/biostatistics/kxj037](https://doi.org/10.1093/biostatistics/kxj037) · PMID: [16632515](https://pubmed.ncbi.nlm.nih.gov/16632515/)
48. **Don't Rule Out Simple Models Prematurely: A Large Scale Benchmark Comparing Linear and Non-linear Classifiers in OpenML**
Benjamin Strang, Peter van der Putten, Jan N van Rijn, Frank Hutter
Advances in Intelligent Data Analysis XVII (2018) <https://doi.org/ggqzq6q>
DOI: [10.1007/978-3-030-01768-2_25](https://doi.org/10.1007/978-3-030-01768-2_25)
49. **Does deep learning always outperform simple linear regression in optical imaging?**
Shuming Jiao, Yang Gao, Jun Feng, Ting Lei, Xiaocong Yuan
arXiv (2020-02-19) <https://arxiv.org/abs/1911.00353>
DOI: [10.1364/oe.382319](https://doi.org/10.1364/oe.382319)

50. **Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set**
Eelke B Lenselink, Niels ten Dijke, Brandon Bongers, George Papadatos, Herman WT van Vlijmen, Wojtek Kowalczyk, Adriaan P IJzerman, Gerard JP van Westen
Journal of Cheminformatics (2017-08-14) <https://doi.org/gbwq98>
DOI: [10.1186/s13321-017-0232-0](https://doi.org/10.1186/s13321-017-0232-0) · PMID: [29086168](https://pubmed.ncbi.nlm.nih.gov/29086168/) · PMCID: [PMC5555960](https://pubmed.ncbi.nlm.nih.gov/PMC5555960/)
51. **Benchmarking deep learning models on large healthcare datasets**
Sanjay Purushotham, Chuizheng Meng, Zhengping Che, Yan Liu
Journal of Biomedical Informatics (2018-07) <https://doi.org/gd97qc>
DOI: [10.1016/j.jbi.2018.04.007](https://doi.org/10.1016/j.jbi.2018.04.007) · PMID: [29879470](https://pubmed.ncbi.nlm.nih.gov/29879470/)
52. **I tried a bunch of things: The dangers of unexpected overfitting in classification of brain data**
Mahan Hosseini, Michael Powell, John Collins, Chloe Callahan-Flintoft, William Jones, Howard Bowman, Brad Wyble
Neuroscience & Biobehavioral Reviews (2020-12) <https://doi.org/ghkskv>
DOI: [10.1016/j.neubiorev.2020.09.036](https://doi.org/10.1016/j.neubiorev.2020.09.036) · PMID: [33035522](https://pubmed.ncbi.nlm.nih.gov/33035522/)
53. **Massive single-cell RNA-seq analysis and imputation via deep learning**
Yue Deng, Feng Bao, Qionghai Dai, Lani F Wu, Steven J Altschuler
Cold Spring Harbor Laboratory (2018-05-06) <https://doi.org/gfgrpm>
DOI: [10.1101/315556](https://doi.org/10.1101/315556)
54. **A global immune gene expression signature for human cancers**
Yuxin Liu
Oncotarget (2019-03-08) <https://doi.org/gqzq8j>
DOI: [10.18632/oncotarget.26773](https://doi.org/10.18632/oncotarget.26773) · PMID: [30956779](https://pubmed.ncbi.nlm.nih.gov/30956779/) · PMCID: [PMC6443003](https://pubmed.ncbi.nlm.nih.gov/PMC6443003/)
55. **A Four-Biomarker Blood Signature Discriminates Systemic Inflammation Due to Viral Infection Versus Other Etiologies**
DL Sampson, BA Fox, TD Yager, S Bhide, S Cermelli, LC McHugh, TA Seldon, RA Brandon, E Sullivan, JJ Zimmerman, ... RB Brandon
Scientific Reports (2017-06-06) <https://doi.org/gc4zdw>
DOI: [10.1038/s41598-017-02325-8](https://doi.org/10.1038/s41598-017-02325-8) · PMID: [28588308](https://pubmed.ncbi.nlm.nih.gov/28588308/) · PMCID: [PMC5460227](https://pubmed.ncbi.nlm.nih.gov/PMC5460227/)
56. **Multitask learning improves prediction of cancer drug sensitivity**
Han Yuan, Ivan Paskov, Hristo Paskov, Alvaro J González, Christina S Leslie
Scientific Reports (2016-08-23) <https://doi.org/f8zbhk>
DOI: [10.1038/srep31619](https://doi.org/10.1038/srep31619) · PMID: [27550087](https://pubmed.ncbi.nlm.nih.gov/27550087/) · PMCID: [PMC4994023](https://pubmed.ncbi.nlm.nih.gov/PMC4994023/)
57. **Invariant Risk Minimization**
Martin Arjovsky, Léon Bottou, Ishaan Gulrajani, David Lopez-Paz
arXiv (2020-03-31) <https://arxiv.org/abs/1907.02893>
58. **Invariant Risk Minimization Games**
Kartik Ahuja, Karthikeyan Shanmugam, Kush R Varshney, Amit Dhurandhar
arXiv (2020-03-20) <https://arxiv.org/abs/2002.04692>
59. **Supervised, semi-supervised and unsupervised inference of gene regulatory networks**
SR Maetschke, PB Madhamshettiwar, MJ Davis, MA Ragan
Briefings in Bioinformatics (2013-05-21) <https://doi.org/gccv5w>
DOI: [10.1093/bib/bbt034](https://doi.org/10.1093/bib/bbt034) · PMID: [23698722](https://pubmed.ncbi.nlm.nih.gov/23698722/) · PMCID: [PMC3956069](https://pubmed.ncbi.nlm.nih.gov/PMC3956069/)
60. **recount3: summaries and queries for large-scale RNA-seq expression and splicing**

Christopher Wilks, Shijie C Zheng, Feng Yong Chen, Rone Charles, Brad Solomon, Jonathan P Ling, Eddie Luidy Imada, David Zhang, Lance Joseph, Jeffrey T Leek, ... Ben Langmead
Genome Biology (2021-11-29) <https://doi.org/gnm7zc>
DOI: [10.1186/s13059-021-02533-6](https://doi.org/10.1186/s13059-021-02533-6) · PMID: [34844637](https://pubmed.ncbi.nlm.nih.gov/34844637/) · PMCID: [PMC8628444](https://pubmed.ncbi.nlm.nih.gov/PMC8628444/)

61. **An Overview of Multi-Task Learning in Deep Neural Networks**
Sebastian Ruder
arXiv (2017-06-19) <https://arxiv.org/abs/1706.05098>
62. **refine.bio**
Refine.bio
<https://www.refine.bio>
63. **Citation Indexes for Science**
Eugene Garfield
Science (1955-07-15) <https://doi.org/fnkc4f>
DOI: [10.1126/science.122.3159.108](https://doi.org/10.1126/science.122.3159.108) · PMID: [14385826](https://pubmed.ncbi.nlm.nih.gov/14385826/)
64. **The science of science**
Dashun Wang, Albert-László Barabási
Cambridge University Press (2021)
ISBN: 9781108492669
65. **An index to quantify an individual's scientific research output**
JE Hirsch
Proceedings of the National Academy of Sciences (2005-11-07) <https://doi.org/cbq6dz>
DOI: [10.1073/pnas.0507655102](https://doi.org/10.1073/pnas.0507655102) · PMID: [16275915](https://pubmed.ncbi.nlm.nih.gov/16275915/) · PMCID: [PMC1283832](https://pubmed.ncbi.nlm.nih.gov/PMC1283832/)
66. **The h-index Debate: An Introduction for Librarians**
Cameron Barnes
The Journal of Academic Librarianship (2017-11) <https://doi.org/gcjpk2>
DOI: [10.1016/j.acalib.2017.08.013](https://doi.org/10.1016/j.acalib.2017.08.013)
67. **The h-index is no longer an effective correlate of scientific reputation**
Vladlen Koltun, David Hafner
PLOS ONE (2021-06-28) <https://doi.org/gkzfnr>
DOI: [10.1371/journal.pone.0253397](https://doi.org/10.1371/journal.pone.0253397) · PMID: [34181681](https://pubmed.ncbi.nlm.nih.gov/34181681/) · PMCID: [PMC8238192](https://pubmed.ncbi.nlm.nih.gov/PMC8238192/)
68. **Theory and practise of the g-index**
Leo Egghe
Scientometrics (2006-10) <https://doi.org/dgj3tc>
DOI: [10.1007/s11192-006-0144-7](https://doi.org/10.1007/s11192-006-0144-7)
69. **New Tools for Improving and Evaluating The Effectiveness of Research**
<http://www.garfield.library.upenn.edu/papers/onrpaper.html>
70. <https://crln.acrl.org/index.php/crlnews/article/viewFile/7804/7804>
71. **Scimago Journal & Country Rank** <https://www.scimagojr.com/>
72. **A systematic empirical comparison of different approaches for normalizing citation impact indicators**
Ludo Waltman, Nees Jan van Eck
Journal of Informetrics (2013-10) <https://doi.org/f5jdr5>
DOI: [10.1016/j.joi.2013.08.002](https://doi.org/10.1016/j.joi.2013.08.002)

73. **The PageRank Citation Ranking: Bringing Order to the Web.**
Lawrence Page, Sergey Brin, Rajeev Motwani, Terry Winograd
(1999-11-11) <http://ilpubs.stanford.edu:8090/422/>
74. **Maps of random walks on complex networks reveal community structure**
Martin Rosvall, Carl T Bergstrom
Proceedings of the National Academy of Sciences (2008-01-29) <https://doi.org/fw5xcm>
DOI: [10.1073/pnas.0706851105](https://doi.org/10.1073/pnas.0706851105) · PMID: [18216267](https://pubmed.ncbi.nlm.nih.gov/18216267/) · PMCID: [PMC2234100](https://pubmed.ncbi.nlm.nih.gov/PMC2234100/)
75. **Large teams develop and small teams disrupt science and technology**
Lingfei Wu, Dashun Wang, James A Evans
Nature (2019-02) <https://doi.org/gfvnb9>
DOI: [10.1038/s41586-019-0941-9](https://doi.org/10.1038/s41586-019-0941-9) · PMID: [30760923](https://pubmed.ncbi.nlm.nih.gov/30760923/)
76. **Are disruption index indicators convergently valid? The comparison of several indicator variants with assessments by peers**
Lutz Bornmann, Sitaram Devarakonda, Alexander Tekles, George Chacko
Quantitative Science Studies (2020-08) <https://doi.org/gq2ts5>
DOI: [10.1162/qss_a_00068](https://doi.org/10.1162/qss_a_00068)
77. **Tradition and Innovation in Scientists' Research Strategies**
Jacob G Foster, Andrey Rzhetsky, James A Evans
American Sociological Review (2015-09-01) <https://doi.org/f7tzm5>
DOI: [10.1177/0003122415601618](https://doi.org/10.1177/0003122415601618)
78. **Bias against novelty in science: A cautionary tale for users of bibliometric indicators**
Jian Wang, Reinhilde Veugelers, Paula Stephan
Research Policy (2017-10) <https://doi.org/gb22vw>
DOI: [10.1016/j.respol.2017.06.006](https://doi.org/10.1016/j.respol.2017.06.006)
79. **Relative Citation Ratio (RCR): A New Metric That Uses Citation Rates to Measure Influence at the Article Level**
Blan Hutchins, Xin Yuan, James M Anderson, George M Santangelo
PLOS Biology (2016-09-06) <https://doi.org/f88zk2>
DOI: [10.1371/journal.pbio.1002541](https://doi.org/10.1371/journal.pbio.1002541) · PMID: [27599104](https://pubmed.ncbi.nlm.nih.gov/27599104/) · PMCID: [PMC5012559](https://pubmed.ncbi.nlm.nih.gov/PMC5012559/)
80. **Measuring contextual citation impact of scientific journals**
Henk F Moed
Journal of Informetrics (2010-07) <https://doi.org/dpbgj9>
DOI: [10.1016/j.joi.2010.01.002](https://doi.org/10.1016/j.joi.2010.01.002)
81. **Collective topical PageRank: a model to evaluate the topic-dependent academic impact of scientific papers**
Yongjun Zhang, Jialin Ma, Zijian Wang, Bolun Chen, Yongtao Yu
Scientometrics (2017-12-23) <https://doi.org/gc4b2s>
DOI: [10.1007/s11192-017-2626-1](https://doi.org/10.1007/s11192-017-2626-1)
82. **Quantifying and suppressing ranking bias in a large citation network**
Giacomo Vaccario, Matus Medo, Nicolas Wider, Manuel Sebastian Mariani
arXiv (2017-08-30) <https://arxiv.org/abs/1703.08071>
DOI: [10.1016/j.joi.2017.05.014](https://doi.org/10.1016/j.joi.2017.05.014)
83. **Clarivate** [https://access.clarivate.com/login?](https://access.clarivate.com/login?app=wos&alternative=true&shibShireURL=https%3A%2F%2Fwww.webofknowledge.com%2F%3Fauth%3DShibboleth&shibReturnURL=https%3A%2F%2Fwww.webofknowledge.com%2F&roaming=true)
[app=wos&alternative=true&shibShireURL=https%3A%2F%2Fwww.webofknowledge.com%2F%3Fauth%3DShibboleth&shibReturnURL=https%3A%2F%2Fwww.webofknowledge.com%2F&roaming=true](https://access.clarivate.com/login?app=wos&alternative=true&shibShireURL=https%3A%2F%2Fwww.webofknowledge.com%2F%3Fauth%3DShibboleth&shibReturnURL=https%3A%2F%2Fwww.webofknowledge.com%2F&roaming=true)

84. **Scopus preview - Scopus - Welcome to Scopus** <https://www.scopus.com/home.uri>
85. **Software review: COCI, the OpenCitations Index of Crossref open DOI-to-DOI citations**
Ivan Heibi, Silvio Peroni, David Shotton
Scientometrics (2019-09-14) <https://doi.org/ggzz8b>
DOI: [10.1007/s11192-019-03217-6](https://doi.org/10.1007/s11192-019-03217-6)
86. **Promise and Pitfalls of Extending Google's PageRank Algorithm to Citation Networks**
S Maslov, S Redner
Journal of Neuroscience (2008-10-29) <https://doi.org/fsfh8w>
DOI: [10.1523/jneurosci.0002-08.2008](https://doi.org/10.1523/jneurosci.0002-08.2008) · PMID: [18971452](https://pubmed.ncbi.nlm.nih.gov/18971452/) · PMCID: [PMC6671494](https://pubmed.ncbi.nlm.nih.gov/PMC6671494/)
87. **Standardizing the Evaluation of Scientific and Academic Performance in Neurosurgery—Critical Review of the “h” Index and its Variants**
Salah G Aoun, Bernard R Bendok, Rudy J Rahme, Ralph G Dacey Jr., HHunt Batjer
World Neurosurgery (2013-11) <https://doi.org/fxtz98>
DOI: [10.1016/j.wneu.2012.01.052](https://doi.org/10.1016/j.wneu.2012.01.052) · PMID: [22381859](https://pubmed.ncbi.nlm.nih.gov/22381859/)
88. **UNDERSTANDING THE LIMITATIONS OF THE JOURNAL IMPACT FACTOR**
ANDREW P KURMIS
The Journal of Bone and Joint Surgery-American Volume (2003-12) <https://doi.org/gh6fph>
DOI: [10.2106/00004623-200312000-00028](https://doi.org/10.2106/00004623-200312000-00028) · PMID: [14668520](https://pubmed.ncbi.nlm.nih.gov/14668520/)
89. **Electronic documents give reproducible research a new meaning**
Jon F Claerbout, Martin Karrenbach
SEG Technical Program Expanded Abstracts 1992 (1992-01) <https://doi.org/b6t7wj>
DOI: [10.1190/1.1822162](https://doi.org/10.1190/1.1822162)
90. **Defining Research Reproducibility: What Do You Mean?**
David Mendoza, Christopher A Garcia
Clinical Chemistry (2017-11-01) <https://doi.org/gq33c8>
DOI: [10.1373/clinchem.2017.279984](https://doi.org/10.1373/clinchem.2017.279984) · PMID: [32100823](https://pubmed.ncbi.nlm.nih.gov/32100823/)
91. **What does research reproducibility mean?**
Steven N Goodman, Daniele Fanelli, John PA Ioannidis
Science Translational Medicine (2016-06) <https://doi.org/gc5sjs>
DOI: [10.1126/scitranslmed.aaf5027](https://doi.org/10.1126/scitranslmed.aaf5027) · PMID: [27252173](https://pubmed.ncbi.nlm.nih.gov/27252173/)
92. **A statistical definition for reproducibility and replicability**
Prasad Patil, Roger D Peng, Jeffrey T Leek
Cold Spring Harbor Laboratory (2016-07-29) <https://doi.org/gftqhv>
DOI: [10.1101/066803](https://doi.org/10.1101/066803)
93. **Reproducibility vs. Replicability: A Brief History of a Confused Terminology**
Hans E Plesser
Frontiers in Neuroinformatics (2018-01-18) <https://doi.org/gc5ptr>
DOI: [10.3389/fninf.2017.00076](https://doi.org/10.3389/fninf.2017.00076) · PMID: [29403370](https://pubmed.ncbi.nlm.nih.gov/29403370/) · PMCID: [PMC5778115](https://pubmed.ncbi.nlm.nih.gov/PMC5778115/)
94. **Reproducible Research in Computational Harmonic Analysis**
David L Donoho, Arian Maleki, Inam Ur Rahman, Morteza Shahram, Victoria Stodden
Computing in Science & Engineering (2009-01) <https://doi.org/fgmqfh>
DOI: [10.1109/mcse.2009.15](https://doi.org/10.1109/mcse.2009.15)
95. **Why trust science?**
Naomi Oreskes
Princeton University Press (2021)

96. **The logic of scientific discovery**
Karl Popper
Routledge (2010)
ISBN: 9780415278447
97. **Computational Reproducibility: The Elephant in the Room**
Les Hatton, Michiel van Genuchten
IEEE Software (2019-03) <https://doi.org/ggkvtr>
DOI: [10.1109/ms.2018.2883805](https://doi.org/10.1109/ms.2018.2883805)
98. **Reproducibility in Scientific Computing**
Peter Ivie, Douglas Thain
ACM Computing Surveys (2019-05-31) <https://doi.org/ggcqyn>
DOI: [10.1145/3186266](https://doi.org/10.1145/3186266)
99. **Raise standards for preclinical cancer research**
CGlenn Begley, Lee M Ellis
Nature (2012-03-28) <https://doi.org/gd3xdh>
DOI: [10.1038/483531a](https://doi.org/10.1038/483531a) · PMID: [22460880](https://pubmed.ncbi.nlm.nih.gov/22460880/)
100. **Believe it or not: how much can we rely on published data on potential drug targets?**
Florian Prinz, Thomas Schlange, Khusru Asadullah
Nature Reviews Drug Discovery (2011-08-31) <https://doi.org/dfsxxb>
DOI: [10.1038/nrd3439-c1](https://doi.org/10.1038/nrd3439-c1) · PMID: [21892149](https://pubmed.ncbi.nlm.nih.gov/21892149/)
101. **Editors' Introduction to the Special Section on Replicability in Psychological Science**
Harold Pashler, Eric-Jan Wagenmakers
Perspectives on Psychological Science (2012-11) <https://doi.org/gckf56>
DOI: [10.1177/1745691612465253](https://doi.org/10.1177/1745691612465253) · PMID: [26168108](https://pubmed.ncbi.nlm.nih.gov/26168108/)
102. **High-Resolution Image Synthesis with Latent Diffusion Models**
Robin Rombach, Andreas Blattmann, Dominik Lorenz, Patrick Esser, Björn Ommer
arXiv (2022-04-14) <https://arxiv.org/abs/2112.10752>
103. **Learning from reproducing computational results: introducing three principles and the <i>Reproduction Package</i>**
MS Krafczyk, A Shi, A Bhaskar, D Marinov, V Stodden
Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences (2021-03-29) <https://doi.org/gmgpgz>
DOI: [10.1098/rsta.2020.0069](https://doi.org/10.1098/rsta.2020.0069) · PMID: [33775145](https://pubmed.ncbi.nlm.nih.gov/33775145/) · PMCID: [PMC8059663](https://pubmed.ncbi.nlm.nih.gov/PMC8059663/)
104. **Reproducible Research in Computational Science**
Roger D Peng
Science (2011-12-02) <https://doi.org/fdv356>
DOI: [10.1126/science.1213847](https://doi.org/10.1126/science.1213847) · PMID: [22144613](https://pubmed.ncbi.nlm.nih.gov/22144613/) · PMCID: [PMC3383002](https://pubmed.ncbi.nlm.nih.gov/PMC3383002/)